{"id":"rhtpo-combined-with-herombopag-csa","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Infection (from immunosuppression)"},{"rate":null,"effect":"Renal dysfunction (CsA-related)"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL3038082","moleculeType":"Protein","molecularWeight":"1361.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Recombinant human thrombopoietin (rhTPO) directly stimulates megakaryopoiesis and platelet production by activating the thrombopoietin receptor. Eltrombopag (Herombopag) is an oral thrombopoietin receptor agonist that further enhances platelet generation. Cyclosporine A (CsA) provides immunosuppressive effects to reduce T-cell mediated destruction of platelets and bone marrow progenitors, addressing the immune component of thrombocytopenia.","oneSentence":"This combination therapy stimulates platelet production through thrombopoietin receptor agonism while suppressing immune-mediated platelet destruction via immunosuppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:00.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"},{"name":"Aplastic anemia with thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT06004791","phase":"PHASE4","title":"A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Aplastic Anemia, Drug Effect","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["experimental"],"phase":"marketed","status":"active","brandName":"rhTPO combined with Herombopag + CsA","genericName":"rhTPO combined with Herombopag + CsA","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy stimulates platelet production through thrombopoietin receptor agonism while suppressing immune-mediated platelet destruction via immunosuppression. Used for Immune thrombocytopenia (ITP), Aplastic anemia with thrombocytopenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}